Bicara Therapeutics(BCAX.US)

Last Updated 19:00:00 ET
longbridge loading

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Market Beat·
US
BCAX
+2.27%
US
BBH
+0.45%
Market Beat·
US
BCAX
+2.27%
US
BBH
+0.45%

Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Tip Ranks·
US
BCAX
+2.27%
Tip Ranks·
US
BCAX
+2.27%

Bicara Therapeutics hires Replimune, Sanofi alum as CCO

Fiercepharma·
US
REPL
+5.64%
US
SNY
+2.11%
US
BCAX
+2.27%
Fiercepharma·
US
REPL
+5.64%
US
SNY
+2.11%
US
BCAX
+2.27%

Bicara Records $56 Mln Loss In Q1; Provides Updates On Ficerafusp Alfa Trials

nasdaq·
US
BCAX
+2.27%
nasdaq·
US
BCAX
+2.27%

Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results.

benzinga_article·
US
BCAX
+2.27%
US
XBI
+3.30%
US
FBT
+1.25%
benzinga_article·
US
BCAX
+2.27%
US
XBI
+3.30%
US
FBT
+1.25%

Bicara Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
BCAX
+2.27%
Earnings Watch·
US
BCAX
+2.27%

Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday

Market Beat·
US
BCAX
+2.27%
Market Beat·
US
BCAX
+2.27%
© 2026 Longbridge｜Disclaimer